Skoda R - Search Results

1

Dkk3 levels in patients with myeloproliferative neoplasms.

Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ. Medinger M, et al. Among authors: skoda r. Thromb Res. 2014 Feb;133(2):218-21. doi: 10.1016/j.thromres.2013.11.003. Epub 2013 Nov 14. Thromb Res. 2014. PMID: 24309205

2

Myeloproliferative disorders: complications, survival and causes of death.

Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Brodmann S, et al. Among authors: skoda rc. Ann Hematol. 2000 Jun;79(6):312-8. doi: 10.1007/s002779900136. Ann Hematol. 2000. PMID: 10901610

3

Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.

Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC. Kralovics R, et al. Among authors: skoda rc. Blood. 2003 Sep 1;102(5):1869-71. doi: 10.1182/blood-2003-03-0744. Epub 2003 May 1. Blood. 2003. PMID: 12730106 Free article.

4

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. Kralovics R, et al. Among authors: skoda rc. N Engl J Med. 2005 Apr 28;352(17):1779-90. doi: 10.1056/NEJMoa051113. N Engl J Med. 2005. PMID: 15858187 Free article.

5

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, Passamonti F, Pietra D, Cazzola M, Skoda RC. Kralovics R, et al. Among authors: skoda rc. Blood. 2005 Nov 15;106(10):3374-6. doi: 10.1182/blood-2005-05-1889. Epub 2005 Aug 4. Blood. 2005. PMID: 16081684 Free article.

6

Lessons from familial myeloproliferative disorders.

Skoda R, Prchal JT. Skoda R, et al. Semin Hematol. 2005 Oct;42(4):266-73. doi: 10.1053/j.seminhematol.2005.08.002. Semin Hematol. 2005. PMID: 16210040 Review.

7

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC. Kralovics R, et al. Among authors: skoda rc. Blood. 2006 Aug 15;108(4):1377-80. doi: 10.1182/blood-2005-11-009605. Epub 2006 May 4. Blood. 2006. PMID: 16675710 Free article. Clinical Trial.

8

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC. Theocharides A, et al. Among authors: skoda rc. Blood. 2007 Jul 1;110(1):375-9. doi: 10.1182/blood-2006-12-062125. Epub 2007 Mar 15. Blood. 2007. PMID: 17363731 Free article.

9

Myeloproliferative disorders: a time of new definitions. Outflow from New Horizons in Haematology Meeting, 9-10 March 2007.

Skoda R, Barbui T, Reilly JT. Skoda R, et al. Eur J Haematol Suppl. 2007 Oct;(68):1. doi: 10.1111/j.1600-0609.2007.00933.x. Eur J Haematol Suppl. 2007. PMID: 17727555 No abstract available.

10

Advances in the understanding and management of myeloproliferative disorders.

Skoda R. Skoda R. Eur J Haematol Suppl. 2007 Oct;(68):2-4. doi: 10.1111/j.1600-0609.2007.00934.x. Eur J Haematol Suppl. 2007. PMID: 17727556 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Search Page

Filters